LUND, Sweden, April 29, 2021 /PRNewswire/ -- The Annual
General Meeting ("AGM") of BioInvent International AB ("BioInvent")
(Nasdaq Stockholm: BINV) resolved to elect Vincent Ossipow as new Board member and to
re-elect the Board members Kristoffer
Bissessar, Dharminder Chahal,
Thomas Hecht, Leonard Kruimer and Bernd Seizinger.
The AGM voted in favor of adopting the income statements and
balance sheets for the Group and the parent company for the
financial year 2020 and decided that no dividend should be declared
for the financial year 2020.
The AGM discharged the Board members and the CEO from liability,
re-elected the Board members Kristoffer
Bissessar, Dharminder Chahal,
Thomas Hecht, Leonard Kruimer and Bernd Seizinger, and elected Vincent Ossipow as new Board member.
Leonard Kruimer was re-elected
Chairman of the Board.
The AGM resolved that the Board's fee shall amount to
SEK 682,500 to the Chairman of the
Board and SEK 325,000 to each of the
other Board members, who are not employed by the company. In
addition hereto, the AGM resolved on fees for committee work of (i)
SEK 70,000 to the Chairman of the
Audit Committee and SEK 50,000 to
other members of the Audit Committee, (ii) SEK 35,000 to the Chairman of the Remuneration
Committee and SEK 25,000 to other
members of the Remuneration Committee, and (iii) SEK 70,000 to the Chairman of the Scientific
Committee and SEK 50,000 to other
members of the Scientific Committee.
The AGM resolved to adopt the report regarding compensation
pursuant to Chapter 8, Section 53 a of the Swedish Companies Act in
accordance with the Board of Directors' proposal.
Further, the AGM resolved, in accordance with the Board's
proposal, to amend to the Articles of Association in order to be
able to use the alternatives provided by the Swedish Companies Act
to decide on proxy collection and postal voting.
Last, the AGM authorized the Board of Directors to resolve on
the issue of new shares, on one or several occasions during the
period up to the next annual general meeting. The number of shares
to be issued by virtue of the authorization shall not entail a
dilution effect of more than 20 per cent of the registered share
capital after completed issue. The issue may take place with or
without a deviation from the shareholders' preferential right and
with or without provisions on contribution in kind or set-off or
any other terms. The purpose of the authorization is to increase
the company's financial flexibility and enable acquisitions by
payment of shares. If the Board resolves on an issue with deviation
from the shareholders' preferential right the reason may be to add
new capital and/or new company owners of strategic importance to
the company and/or the acquisition of other companies or
businesses. At a deviation from the shareholders' preferential
right, the issue rate shall be determined in accordance with market
conditions. Other terms may be resolved by the Board.
The minutes from the AGM will be available on the Company's
website, www.bioinvent.com.
About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a
clinical-stage biotech company that discovers and develops novel
and first-in-class immuno-modulatory antibodies for cancer therapy,
with currently three drug candidates in four ongoing clinical
programs in Phase 1/2 trials for the treatment of hematological
cancer and solid tumors, respectively. The Company's validated,
proprietary F.I.R.S.T™ technology platform simultaneously
identifies both targets and the antibodies that bind to them,
generating many promising new drug candidates to fuel the Company's
own clinical development pipeline or for additional licensing and
partnering.
The Company generates revenues from research collaborations and
license agreements with multiple top-tier pharmaceutical companies,
as well as from producing antibodies for third parties in the
Company's fully integrated manufacturing unit. More information is
available at www.bioinvent.com.
For further information, please contact:
Cecilia Hofvander
Senior Director Investor Relations
+46 (0)46 286 85 50
cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No. Org nr: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
The information was submitted for publication at 11:10 a.m. CEST on April
29, 2021.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/bioinvent-international-ab/r/resolutions-at-bioinvent-s-annual-general-meeting-2021,c3336767
The following files are available for download:
https://mb.cision.com/Main/583/3336767/1409939.pdf
|
Resolutions at
BioInvent’s Annual General Meeting 2021
|
View original
content:http://www.prnewswire.com/news-releases/resolutions-at-bioinvents-annual-general-meeting-2021-301279972.html
SOURCE BioInvent International AB